+ All Categories
Home > Documents > Presentazione standard di PowerPoint · 2020. 10. 15. · C9orf72, GRN and MAPT - clinical and...

Presentazione standard di PowerPoint · 2020. 10. 15. · C9orf72, GRN and MAPT - clinical and...

Date post: 01-Feb-2021
Category:
Upload: others
View: 0 times
Download: 0 times
Share this document with a friend
31
Isabelle Le Ber Reference centre on rare dementias & Brain and spine institute-ICM CNRS UMR7225, INSERM UMR_S1127, UPMC U75, Paris Parkinsonism-dementia genetics C9orf72, GRN and MAPT - clinical and genetic aspects
Transcript
  • Isabelle Le Ber

    Reference centre on rare dementias& Brain and spine institute-ICM

    CNRS UMR7225, INSERM UMR_S1127, UPMC U75, Paris

    Parkinsonism-dementia genetics

    C9orf72, GRN and MAPT - clinical and genetic aspects

    http://icm-institute.org/

  • Disclosures

    Scientific board of Prevail therapeutics

  • 1995 2000 2005 2010 2015

    FTLD

    gen

    es

    MAPTVCP

    CHMP2B

    GRN

    DCTN1 TARDBP

    ANGFUSOPTN

    C9orf72SQSTM1

    CSF1R

    PFN1

    MATR3

    UBQLN2

    CHCHD10

    TBK1

    CCNF

    TREM2

    2020

    Sanger sequencing Next generation sequencing

    GRN 25%

    C9orf7225%

    MAPT15%

    Others15%

    Unknown 20%

    Genetics of frontotemporal lobar degeneration an increasing complexity

  • Holler et al., 2017

    Genetics of frontotemporal lobar degeneration Pathomechanisms of FTD mutations - GRN

    Nonsense,

    Frameshift

    Deletions

    Sellami et al., 2020

    Progranulin haploinsuficiency

    Cut-off value 71

  • Genetics of frontotemporal lobar degeneration Pathomechanisms of FTD mutations – C9orf72

    Ling, Polimenidou & Cleveland, 2013

    Pathogenic >30 G4C2

  • 4100 5 6 1110 144a 87

    12

    139 122 317q21

    Genetics of frontotemporal lobar degeneration Pathomechanisms of FTD mutations – MAPT

    0N3R

    1N3R

    2N3R

    0N4R

    2N4R

    1N4R

    4 or 3 MTBD

    E10

    TAU

    Microtubule

    3 microtubule domains (3R, exon 10-) 4 four microtubule domains (4R, exon 10+)

    Missense mutations in exons 9, 11-12 Reduce MT assembly (3&4R in N)

    Exon 10 and intronic mutations Ex 10 splicing - ↗ 4R/3R ratio (4R in N&G)

  • • PNFA• SD • bvFTD• FTD-Parkinsonism

    • Behavioural variant FTD (bvFTD) / bvFTD-Parkinsonism

    • Semantic variant of Primary Progressive aphasia (svPPA)

    • Non-fluent variant of PPA (nvfPPA/PNFA)

    Behavior

    Language

    Clinical spectrum of frontotemporal lobar degeneration :

    FTLD

  • • PNFA• SD • bvFTD• FTD-Parkinsonism

    • Behavioural variant FTD (bvFTD) / bvFTD-Parkinsonism

    • Semantic variant of Primary Progressive aphasia (svPPA)

    • Non-fluent variant of PPA (nvfPPA/PNFA)

    • FTD associated with Amyotrophic Lateral Sclerosis (FTD-ALS)

    • Corticobasal syndrome (CBS)

    • Progressive supranuclear palsy syndrome (PSPS)

    Behavior

    Language

    Parkinsonism

    ALS

    Clinical spectrum of frontotemporal lobar degeneration : At the intersection of ALS and parkinsonism

    ParkinsonismFTLDALS

    • FTD/ALS• ALS • PSP (4R)• CBS (4R)• FTD/MAPT

  • • PNFA• SD • bvFTD• FTD-Parkinsonism • PSP (4R)

    • CBS (4R)• FTD/MAPT

    Clinical spectrum of frontotemporal lobar degeneration : At the intersection of ALS and parkinsonism

    ParkinsonismFTLDALS

    TDP-43

    TAU

    • FTD/ALS• ALS

    • bvFTD & PNFA: variably TDP-43 or TAU • PSP : TAU, CBS TAU >> TDP-43• SD : TDP43 (type C)• FTD-ALS & ALS : TDP-43

  • 3403 GRN, MAPT and C9orf72 mutation carriers

    Clinical genetic correlations Moore et al., Lancet Neurol, 2020

  • Clinical genetic correlationsMoore et al., Lancet Neurol, 2020

    GRN associated phenotypes: bvFTD ~ 40% >> PPA ~ 13% >> CBS 4%

    • ALS, FTD/ALS & PSP : rare

  • MAPT associated phenotypes : bvFTD ~ 45% >> PSP/CBS ~ 6% > PPA ~ 4%

    Clinical genetic correlationsMoore et al., Lancet Neurol, 2020

    • Epilepsy, psych. Disord.

    •FTD/ALS, ALS rare

  • Clinical genetic correlationsMoore et al., Lancet Neurol, 2020

    C9orf72 phenotypes: bvFTD ~ 30%, ALS ~ 20%, FTD/ALS ~ 11%

    • SD, PNFA, CBS, PSP: possible but rare

    (1-2% each)

  • Clinical genetic correlationsMoore et al., Lancet Neurol, 2020

    C9orf72 phenotypes: bvFTD ~ 30%, ALS ~ 20%, FTD/ALS ~ 11%

    Psychiatric dis. ~ 10-20% Prodromal (jaleousy, paranoia delusions); Late-onset schizophrenia

    • SD, PNFA, CBS, PSP: possible but rare

    (1-2% each)

  • FTD gene mutations and parkinsonian disorders ?

  • • Parkinsonism associated to FTD ?

    • Atypical parkinsonian disorders : PSP & CBS >>> LBD, MSA

    • Do FTD genes directly contribute to/mimick PD phenotype ?

    FTD gene mutations and parkinsonian disorders ?

    .

  • Characteristics of FTD-parkinsonism

  • • All genetic forms of FTLD : GRN (40-60%), MAPT (20-40%) > c9orf72 (10-35%) > others

    • During the disease course, within the 2 first years of FTD

    • Patients with bvFTD or FTD/ALS (rarely associated with PPA or ALS)

    • Typically moderate akinetic-rigid, without resting tremor

    • C9orf72: Postural and action tremor, not at rest (Boeve et al., 2012)

    • Limb > axial, symetric or not

    • Unresponsive or temporary dopa-responsive (rarely sustained during disease course)

    • Datscan -Reduced uptake

    GRNControl c9orf72MAPT

    Characteristics of FTD-parkinsonism

  • Atypical parkinsonian disorders and FTD gene mutations

    • PSP: MAPT >>>> C9orf72, other genes

    • CBS: GRN >> MAPT >>>> other genes

    A dichotomization

  • PSP associated with MAPT mutations

  • 39 patients with PSP carrying MAPT mutations

    PSP associated with MAPT mutations

  • Features predicting MAPT mutations in PSP

    PSP criteria* PSP

    Autopsy confirmed

    (n=100)

    MAPT carriers

    (n=39)

    AA onset, ys 65.2 43.9

    Inheritance Sporadic 90% AD

    Falls, < 1 year 94-100% 25%

    Cognitive/frontal dis., < 2 ys 50% 98%

    Levodopa responsivness Limited/absent Limited/absent

    DaTSCAN Reduced uptake Reduced uptake

    *Litvan et al., 1996; Morris et al., 2003; Resondek et al. 2014; Fujioka et al., 2015; Siuda et al., 2015

    Best predictors of MAPT mutation…

    1. Early AAO

    2. Family history (bvFTD, PSP, CBS)

    3. Absence of early falls

    4. Early frontal dysfunction/dementia

  • CBS associated with GRN mutations35 cases described in the litterature

    Phenotype similar to sporadic CBS, rapidly progressive

    • Asymetric akinetic-rigid syndrome

    • Parietal symptoms, limb/orobuccal apraxia, cortical sensory deficit

    (alien limb is rare)

    • Myoclonus, dystonic postures

    • Frontal behavioural/cognitive dysfunction

    ± Language and visuopatial deficits

    • DatScan: abnormal

    Rademakers et al., 2008; Le Ber et al., 2008; Pickering-Brown et al., 2008; Seelaar et al., 2008; Tartaglia et al., 2010; Picillo et al., 2020

  • CBS associated with GRN mutations

    Whitwell et al., 2007

    35 cases described in the litterature

    Phenotype similar to sporadic CBS, rapidly progressive

    • Asymetric akinetic-rigid syndrome

    • Parietal symptoms, limb/orobuccal apraxia, cortical sensory deficit

    (alien limb is rare)

    • Myoclonus, dystonic postures

    • Frontal behavioural/cognitive dysfunction

    ± Language and visuopatial deficits

    • DatScan: abnormal

    Evocative features

    • Brain MRI : marked asymetry, frontal to parietal regions,

    WM HS

    • Family history combining bvFTD, PPA, CBS (90%)

    • Progranulin plasma level decreased GRN CBS

    Cut-off value 71

  • FTD genes and IPD phenotype ?

  • Possible…..

    Frequency early cognitive disordersFamily history of FTD & ALS

    Early AAO

    FTD genes and IPD phenotype ?

    C9orf72: lower limb, favorable dopa responsiveness, dyskinesias

  • Moore et al., Lancet Neurol, 2020

    … but rare !

    FTD genes and IPD phenotype ?

  • Puschmann et al. 2013

    Recommandations for testing FTD genes in parkisnonian disorders

    • Parkinsonism associated with FTD: all genes

    • Parkinsonism associated with ALS and/or FTD : C9orf72

    • PSP: MAPT >>> C9orf72

    • CBS: GRN (plasma) >>> MAPT

    • PD phenotype: according to family history (FTD/ALS) & AAO

    When and what to test ?

  • • Symptomatic individuals (expert centres, consents)

    • NGS and gene panels allow for multiple genes of different diseasespectrum (FTD, PD) to be tested at the same time (except C9orf72)

    • Sometimes pathogenicity of variants is difficult to establish (VUS)

    • Delicate interpretation when variants of unknwon pathogencity arefound in association with unexpected phenotype

    • Some people may carry two mutations

    When and what to test ?

  • Thanks for your attention


Recommended